Benchmark analyst Bill Sutherland downgraded Amedisys (AMED) to Hold from Buy after the company accepted UnitedHealth’s (UNH) Optum’s all-cash offer to be acquired for $101 per share, which was sweetened by 1% from the original offer in May, and Option Care Health (OPCH) announced that it had terminated its agreement to combine with Amedisys. The firm is lower its rating to Hold, acknowledging the current arbitrage opportunity given the $101 per share take-out price.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMED:
- Amedisys price target raised to $101 from $97 at Truist
- Amedisys price target raised to $101 from $88 at Barclays
- UNH Gains Slightly after Announcing New Merger Deal
- Option Care Health confirms termination of merger agreement with Amedisys
- Amedisys to combine with Optum in all-cash deal at $101 per share